PDD00017273

Catalog No.S8862 Batch:S886201

Technical Data

Formula

C₂₃H₂₆N₆O₄S₂

Molecular Weight

514.62

CAS No.

1945950-21-9

Solubility (25°C)*

In vitro

DMSO

100 mg/mL (194.31 mM)

Water

Insoluble

Ethanol

Insoluble

In Vivo (Add solvents to the product individually and in order.)

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

PDD00017273 is a potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor with an IC50 of 26 nM. This compound exhibits >350-fold selectivity for PARG over a panel of ion channels, enzymes and receptors, including PARP1 and ARH3.

Targets

PARG
(Cell-free assay)

26 nM

Protocol (from reference)

Cell Assay:^{^[1]}	Cell Lines Hela cells Concentrations 0.01-30 μM Incubation Time 72 h Method HeLa cells are seeded in 30 μL media at 1×10⁴ cells/mL in 384-well plates. 16-24 h later, cells are treated with this compound (8 pt dose response, 0.01-30 μM, triplicates) or vehicle (DMSO) control. The outer wells are left un-dosed to account for edge effects. After 72 h, 50 μL of 3.7% Formaldehyde/PBS is added to each well and cells are fixed for 20 min. Cells are then rinsed twice with PBS and stained for 1 h with Hoechst 33342/PBS (1:2000) in the dark. After two further rinses with PBS, images are captured and nuclei counted on a CellInsight.

Cell Assay:^{^[1]}

Cell Lines
Hela cells
Concentrations
0.01-30 μM
Incubation Time
72 h
Method
HeLa cells are seeded in 30 μL media at 1×10⁴ cells/mL in 384-well plates. 16-24 h later, cells are treated with this compound (8 pt dose response, 0.01-30 μM, triplicates) or vehicle (DMSO) control. The outer wells are left un-dosed to account for edge effects. After 72 h, 50 μL of 3.7% Formaldehyde/PBS is added to each well and cells are fixed for 20 min. Cells are then rinsed twice with PBS and stained for 1 h with Hoechst 33342/PBS (1:2000) in the dark. After two further rinses with PBS, images are captured and nuclei counted on a CellInsight.

References

https://pubmed.ncbi.nlm.nih.gov/27689388/

Sellecks PDD00017273 Has Been Cited by 18 Publications

XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites [ Nucleic Acids Res, 2025, 53(4)gkaf086]	PubMed: 39970298
The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor [ Oncogene, 2025, 44(29):2515-2529]	PubMed: 40316740
PARP1 promotes replication-independent DNA double-strand break formation after acute DNA-methylation damage [ bioRxiv, 2025, 2025.07.10.663928]	PubMed: 40672314
SLX4IP acts in parallel to FANCM to limit BLM-dependent replication stress at ALT telomeres [ bioRxiv, 2025, 2025.05.28.656696]	PubMed: 40501906
FANCA Deficiency Induces Oncogenic R-Loop Dependent Synthetic Lethality with PARP1 Inhibitors [ Res Sq, 2025, rs.3.rs-6080272]	PubMed: 40630542
PARP enzyme de novo synthesis of protein-free poly(ADP-ribose) [ Mol Cell, 2024, S1097-2765(24)00864-5]	PubMed: 39536748
SNF2L suppresses nascent DNA gap formation to promote DNA synthesis [ Nucleic Acids Res, 2024, gkae903]	PubMed: 39413208
Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader [ Cell Death Dis, 2024, 15(12):898]	PubMed: 39695097
CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer [ Cell Death Discov, 2024, 10(1):278]	PubMed: 38862485
The three-dimensional structure of the EBV genome plays a crucial role in regulating viral gene expression in EBVaGC [ Nucleic Acids Res, 2023, 10.1093/nar/gkad936]	PubMed: 37889078

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.